{
    "Trade/Device Name(s)": [
        "Carolina Liquid Chemistries Cocaine and Cocaine Metabolite Enzyme Immunoassay (COCM) Test System"
    ],
    "Submitter Information": "Carolina Liquid Chemistries, Corp.",
    "510(k) Number": "K213211",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020763"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "September 27, 2021",
    "Summary Letter Received Date": "September 29, 2021",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Carolina Liquid Chemistries CLC6410 automated clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Test System",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Carolina Liquid Chemistries COCM enzyme immunoassay test system for qualitative detection of benzoylecgonine (cocaine metabolite) in urine",
    "Indications for Use Summary": "Qualitative determination of benzoylecgonine (cocaine metabolite) in human urine at a cutoff of 300 ng/mL for rapid screening; intended for professional use with CLC6410 analyzer, with confirmatory testing by GC/MS or LC/MS recommended.",
    "fda_folder": "Toxicology"
}